ALTUS SCIENCE LIMITED

Company number 07832730 ·

Active

This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.

Financial Health Assessment: ALTUS SCIENCE LIMITED

1. Financial Health Score: B-

The company demonstrates a fundamentally sound balance sheet with healthy liquidity and a long track record of wealth accumulation. However, the most recent financial year (ending November 2025) reveals a significant contraction in both cash reserves and net assets that warrants careful attention. The score reflects a business that appears structurally healthy but is showing symptoms that require diagnosis and monitoring — much like a patient whose vital signs are stable but who has experienced a sudden, notable change in condition.


2. Key Vital Signs

Balance Sheet Strength

Metric 2025 2024 Trend
Net Assets £1,386,626 £2,753,289 ↓ 49.6%
Cash at Bank £523,459 £2,052,260 ↓ 74.5%
Total Assets £2,159,809 £3,434,596 ↓ 37.1%
Total Liabilities £673,713 £576,690 ↑ 16.8%
Shareholders' Funds £1,386,626 £2,753,289 ↓ 49.6%

Liquidity Indicators

Metric 2025 2024 Interpretation
Current Ratio 2.14 4.72 Healthy but significantly weakened
Quick Ratio (ex-stock) 1.75 4.38 Adequate short-term coverage
Working Capital £765,674 £2,145,493 Still positive, but reduced
Cash as % of Current Assets 36.4% 75.4% Shift toward less liquid assets

Operational Indicators

Metric 2025 2024 Interpretation
Debtors £656,863 £470,325 ↑ 39.7% — growing sales or slower payment
Stocks £259,065 £199,598 ↑ 29.8% — building inventory
Employees (avg monthly) 27 23 ↑ 17.4% — expanding workforce
Fixed Asset Additions £179,136 — Significant capital investment

Long-Term Wealth Creation (Net Assets Trajectory)

Year Net Assets Year-on-Year Change
2016 £394,724 —
2017 £625,588 +58.5%
2018 £1,092,891 +74.7%
2019 £713,379 -34.7%
2020 £98,965 -86.1%
2021 £501,576 +406.7%
2022 £1,242,318 +147.7%
2023 £1,984,646 +59.8%
2024 £2,753,289 +38.7%
2025 £1,386,626 -49.6%

3. Diagnosis

What the Financial Data Reveals About Business Health

Overall Condition: Fundamentally sound with a recent episode of significant cash outflow

Think of this company as a patient who has been in robust health for years, building strength steadily, but who has just experienced a notable event — a sudden drop in cash reserves of approximately £1.53 million and a reduction in net assets of approximately £1.37 million. The question is whether this represents a planned, healthy action (like an athlete deliberately shedding weight for a competition) or a symptom of underlying illness.

Positive Indicators — Signs of a Healthy Constitution

Strong accumulated wealth: Over a decade of trading, the company has built substantial retained profits of £1,386,525 in its P&L reserve. This is the financial equivalent of a strong immune system — the business has significant reserves to weather challenges.

Positive working capital: Net current assets of £765,674 mean the company can comfortably meet its short-term obligations. The current ratio of 2.14 indicates that for every £1 of short-term debts, the company has £2.14 in short-term assets. This is a healthy reading, though down from the exceptionally strong 4.72 in 2024.

Operational expansion: The increase in employee headcount from 23 to 27, combined with rising debtor balances (+39.7%) and stock levels (+29.8%), suggests the business is growing its activity levels. This is consistent with a company investing in future revenue generation.

Significant capital investment: Fixed asset additions of £179,136 in 2025 indicate ongoing investment in plant and machinery, leasehold improvements, and fixtures — the business is reinvesting in its productive capacity. This is a positive sign of confidence in future operations.

Low gearing: The company has minimal long-term debt (£4,604 in creditors falling due after more than one year) and is not highly leveraged. This means it is not burdened by significant interest payments or debt service obligations.

Symptoms Requiring Investigation

Dramatic cash reduction: The £1.53 million decline in cash is the most prominent symptom. While the company still holds £523,459 in cash — a healthy absolute figure — the scale of the reduction is significant. This is the financial equivalent of a sudden drop in blood pressure: it may be entirely benign (a planned intervention) or it may signal an underlying issue.

Probable dividend extraction: By reconstructing the cash flow movements, we can account for approximately £323,000 of the cash reduction through working capital changes (increased debtors and stock) and capital investment. The remaining approximately £1.2 million is most likely explained by dividend payments to the two shareholder-directors (Graham and name shown to subscribers). This interpretation is supported by the fact that net assets declined by £1,366,663 — consistent with a substantial dividend distribution following a very strong year in 2024. If this is the case, it represents a planned extraction of accumulated wealth by the owners rather than a symptom of business distress.

Historical volatility: The net assets trajectory reveals that this is not the first time the company has experienced significant swings. In 2019-2020, net assets fell from £1.09 million to just £98,965 — a dramatic decline — before recovering strongly. This pattern suggests the owners may periodically extract value from the business, creating a "saw-tooth" pattern of wealth accumulation and distribution. This is not uncommon in owner-managed private companies but does create periods of reduced financial resilience.

Rising debtor balances: The 39.7% increase in debtors could indicate either healthy sales growth or deteriorating collection performance. Without turnover figures (the company uses small company exemptions and does not file a P&L account), it is difficult to determine which. If debtors are growing faster than sales, this would be a symptom of weakening credit control — akin to a circulatory system where blood is not returning efficiently to the heart.

Increasing stock levels: The 29.8% increase in stock could reflect deliberate inventory build-up to support growing sales, or it could indicate slow-moving inventory. The stock valuation policy (lower of cost and estimated selling price less costs to complete) is standard, but the increase warrants monitoring to ensure stock remains turnable and does not become obsolete — particularly important for a chemical products manufacturer where shelf-life may be a consideration.

Prognosis

Short-term outlook: Stable The company has adequate liquidity, a strong balance sheet, and appears to be operationally expanding. Even after the significant cash reduction, the business retains sufficient resources to meet its obligations and fund ongoing operations. The current ratio of 2.14 provides a comfortable buffer.

Medium-term outlook: Cautiously optimistic The increase in employees, investment in fixed assets, and growth in debtor/stock balances all suggest a business that is expanding. If this expansion translates into proportionate revenue growth, the company should rebuild its cash position over time. However, the business is more vulnerable to shocks than it was in 2024, with reduced cash reserves to absorb unexpected costs or downturns.

Key risk factors: - If the 2025 cash reduction reflects trading losses rather than dividends, this would be a serious concern requiring immediate attention - The company's history of volatility (particularly the 2019-2020 decline) suggests it may be susceptible to cyclical or market-driven downturns - As a manufacturer of chemical products (SIC 20590), the business may be exposed to raw material cost fluctuations, regulatory changes, and supply chain risks - The concentration of ownership in two individuals (Mr and name shown to subscribers) creates key-person dependency risk


4. Recommendations

Immediate Actions

1. Confirm the nature of the 2025 cash outflow The single most important step is to understand whether the £1.53 million cash reduction was primarily dividend extraction or trading losses. If dividends, the business remains fundamentally healthy. If losses, urgent corrective action is needed. Review the full P&L account (not filed publicly but available internally) to confirm.

2. Strengthen debtor management With debtors rising 39.7%, implement tighter credit control procedures. Review aged debtor reports, set clear payment terms, and consider early payment incentives. The financial equivalent of improving circulation — ensure cash returns to the business promptly.

3. Monitor stock turnover Given the 29.8% increase in stock for a chemical products business, assess stock aging and turnover ratios. Identify any slow-moving or obsolete items and write them down promptly. Implement just-in-time purchasing where feasible to reduce capital tied up in inventory.

Medium-Term Actions

4. Rebuild cash reserves Establish a target minimum cash balance (e.g., 3-6 months of operating costs) and prioritise rebuilding toward this level before considering further significant dividend distributions. This creates a financial "emergency fund" — the business equivalent of maintaining adequate reserves.

5. Diversify customer base Review concentration of debtor balances. If a significant proportion of the £656,863 debtor balance is owed by a small number of customers, this represents a concentration risk. A healthy patient doesn't rely on a single organ to sustain the whole body.

6. Review pricing and margins Without turnover data, it is impossible to assess margin trends. Internally, monitor gross margins by product line and ensure pricing keeps pace with input cost inflation, particularly for raw materials in the chemical manufacturing sector.

Long-Term Actions

7. Develop a formal dividend policy Given the historical pattern of volatility, establish a formal dividend policy that balances owner rewards with business resilience. For example, commit to maintaining minimum net assets and cash thresholds before declaring dividends, and cap dividend payouts at a percentage of annual profits.

8. Invest in financial reporting and forecasting Implement rolling 12-month cash flow forecasts and quarterly management accounts. This will provide early warning signs of any deterioration — the financial equivalent of regular health check-ups rather than waiting for symptoms to appear.

9. Consider succession planning With ownership concentrated in two individuals who also serve as the sole directors, develop succession and contingency plans. This protects the business's long-term viability and ensures continuity of operations and leadership.


5. Summary Assessment

Altus Science Limited is a financially robust company with over a decade of trading history and accumulated net assets of £1.39 million. The business appears to be growing operationally, with increased headcount, capital investment, and expanding debtor and stock balances. The most significant concern is the dramatic reduction in cash and net assets in the latest financial year, which most likely reflects a substantial dividend extraction by the owner-directors following an exceptional 2024, but which warrants confirmation. The company's liquidity remains adequate, its balance sheet is strong, and its operational indicators point to expansion, though the historical pattern of volatility suggests a need for more disciplined financial management and reserve-building.

Names of the people mentioned are shown to subscribers. See subscription

Perspective: Financial Health Diagnostician · Model: glm-5.2 · Generated 2 November 2026